熱門資訊> 正文
BioCryst Pharmaceuticals任命Donald Fong为首席医疗官
2024-09-05 19:17
- BioCryst Pharmaceuticals (NASDAQ:BCRX) said it has appointed Donald Fong as its new chief medical officer, effective immediately.
- Fong had joined the company in April 2024 as vice president of the ophthalmology therapeutic area,
More on BioCryst Pharmaceuticals
- Betting On BioCryst Pharmaceuticals: Orladeyo's Success Fuels Future Prospects
- Piper lists eight defensive biotechs to face market volatility
- BioCryst up 8% after raising 2024 Orladeyo revenue guidance
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。